San Francisco, CA, USA
Biotechnology · DeepTech · Health
SyntheX created a novel cell-based, synthetic biology-driven drug selection platform, that allows for the efficient synthesis and identification of peptides and macrocycles that selectively disrupt intracellular protein-protein interactions of interest. Although the platform has broad application, the initial focus is on oncology. Targets are selected based on the concepts of synthetic lethality and oncogene addiction, with the first program focused on DNA damage repair and working through a novel cell death mechanism that was uncovered.Something looks off?